Literature DB >> 26686601

Surgical versus medical treatment for children with epileptic encephalopathy in infancy and early childhood: Results of an international multicenter cohort study in Far-East Asia (the FACE study).

Taisuke Otsuki1, Heung-Dong Kim2, Guoming Luan3, Yushi Inoue4, Hiroshi Baba5, Hirokazu Oguni6, Seung-Chyul Hong7, Shigeki Kameyama8, Katsuhiro Kobayashi9, Shinichi Hirose10, Hitoshi Yamamoto11, Shin-ichiro Hamano12, Kenji Sugai13.   

Abstract

OBJECTIVE: To compare the seizure and developmental outcomes in infants and young children with epileptic encephalopathy who have undergone surgical and medical treatments.
METHODS: An international, multicenter, observational cohort study was undertaken. A total of 317 children aged <6 years, who had frequent disabling seizures despite intensive medical treatments, were registered. Among the enrolled children, 250 were treated medically (medical group), 31 underwent resective surgery (resective group), and 36 underwent palliative surgery [callosotomy (n=30) or vagal nerve stimulation (n=6); palliative group] on admission. Seizure and developmental outcomes were obtained for 230 children during the 3-year follow-up period. Cox proportional hazard model was used to adjust for clinical backgrounds among treatment groups when comparing the seizure-free survival rates.
RESULTS: At the 3-year follow-up, seizure-free survival was 15.7%, 32.1%, and 52.4% in the medical, palliative, and resective groups, respectively. The adjusted hazard ratios for seizure recurrence in the resective and palliative groups versus the medical group were 0.43 (95% CI, 0.21-0.87, P=0.019) and 0.82 (95% CI, 0.46-1.46, P=0.50), respectively; the former was statistically significant. Regarding the developmental outcome, the mean DQs in the resective group increased significantly compared to those in the medical group during the follow-up (P<0.01). As for subgroup analysis, better seizure and development outcomes were demonstrated in the resective group compared to the medical group in children with nonsyndromic epilepsies (those to which no known epilepsy syndromes were applicable). SIGNIFICANCE: These results suggest that surgical treatments, particularly resective surgeries, are associated with better seizure and developmental outcomes compared with successive medical treatment. The present observations may facilitate the identification of infants and young children with epileptic encephalopathy who could benefit from surgery.
Copyright © 2015 The Japanese Society of Child Neurology. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Developmental quotient; Epilepsy surgery; Epileptic encephalopathy; Prospective cohort study; Seizure outcome

Mesh:

Year:  2015        PMID: 26686601     DOI: 10.1016/j.braindev.2015.11.004

Source DB:  PubMed          Journal:  Brain Dev        ISSN: 0387-7604            Impact factor:   1.961


  5 in total

Review 1.  Rates and predictors of seizure outcome after corpus callosotomy for drug-resistant epilepsy: a meta-analysis.

Authors:  Alvin Y Chan; John D Rolston; Brian Lee; Sumeet Vadera; Dario J Englot
Journal:  J Neurosurg       Date:  2018-05-01       Impact factor: 5.115

2.  Alteration of the anatomical covariance network after corpus callosotomy in pediatric intractable epilepsy.

Authors:  Riyo Ueda; Hiroshi Matsuda; Noriko Sato; Masaki Iwasaki; Daichi Sone; Eri Takeshita; Yuko Shimizu-Motohashi; Akihiko Ishiyama; Takashi Saito; Hirofumi Komaki; Eiji Nakagawa; Kenji Sugai; Masayuki Sasaki; Yoshimi Kaga; Hiroshige Takeichi; Masumi Inagaki
Journal:  PLoS One       Date:  2019-12-05       Impact factor: 3.240

3.  Corpus Callosotomy: Editorial.

Authors:  Ayataka Fujimoto; Tohru Okanishi
Journal:  Brain Sci       Date:  2022-07-29

Review 4.  Stimulation and Neuromodulation in the Treatment of Epilepsy.

Authors:  Timothy Marc Eastin; Miguel Angel Lopez-Gonzalez
Journal:  Brain Sci       Date:  2017-12-21

Review 5.  Corpus Callosotomy for Controlling Epileptic Spasms: A Proposal for Surgical Selection.

Authors:  Tohru Okanishi; Ayataka Fujimoto
Journal:  Brain Sci       Date:  2021-12-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.